Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma

This is an open-label, Phase II, single-stage study evaluating the use of panitumumab,
paclitaxel, carboplatin and 5FU as an induction regimen in subjects with gastroesophageal
adenocarcinoma. The expectation is that this combination will both increase potential
overall survival by incorporating novel biologic therapy in the neoadjuvant setting and
decrease potential surgical mortality by eliminating pre-operative radiation therapy.